Topic of the Month on ModernWeight: Diet and Exercise on GLP-1s!
Head to the Social Hub to discuss diet and exercise routines when taking GLP-1 medications.
AOMs in the News
This Week's Featured Post
FDA Announces GLP-1 Shortage is Stabilizing—What It Means for Patients
Link: Healthline Article
After months of widespread shortages, the FDA has announced that the supply of GLP-1 drugs, including Mounjaro and Zepbound, is stabilizing. However, this positive news comes with increased demand for compounded versions of these medications, raising concerns about the quality and regulation of these alternatives. This week's featured post dives into the implications of the shortage's end and what patients need to know about compounded drugs.
The shortage of GLP-1 drugs, which has been ongoing for many months, has had a significant impact on people with type 2 diabetes, many of whom rely on these medications for glucose management. The FDA's announcement signals an improvement in supply, but it also highlights the growing demand for these drugs, which could mean more shortages in the future. As GLP-1 medications continue to be in high demand for both weight loss and diabetes management, patients should be prepared for potential ongoing supply challenges.
Why it matters: The end of the GLP-1 drug shortage is a relief for many patients, but the rise in demand for compounded alternatives poses new challenges. Patients should be informed about the potential risks of compounded medications and encouraged to return to FDA-approved options as they become more available. This shift underscores the importance of maintaining high standards in drug manufacturing and patient safety, especially as shortages may persist due to increasing demand.
Who Gets Ozempic? Disparities in Access to GLP-1 Medications
Link: USA Today Article
Access to GLP-1 drugs like Ozempic is unevenly distributed, with patients covered by private insurance and those with more generous health plans being more likely to have their prescriptions filled. A recent study by the University of Southern California highlighted the stark disparities in access to these medications, revealing that Medicare and Medicaid recipients represent a small share of prescription fills. The study found that 90% of Wegovy prescriptions in December 2023 were filled by privately insured patients, while only 1.2% were filled by Medicare beneficiaries.
Why it matters: The growing popularity of GLP-1 medications highlights significant inequities in access to treatment. With most prescriptions filled by privately insured patients, large segments of the population, including those on Medicare and Medicaid, are left without access to these potentially life-saving drugs. This disparity calls for policy changes to ensure more equitable access to GLP-1 medications across all patient groups.
Understanding the Benefits and Managing the Adverse Effects of GLP-1 Receptor Agonists
Link: Drug Topics Article
GLP-1 receptor agonists are highly effective for weight loss and managing obesity-related conditions, but they can also lead to gastrointestinal side effects that some patients find challenging. In a Q&A, Dr. Robert Kushner from Northwestern University discusses the benefits of these therapies and offers strategies for managing adverse effects like nausea, diarrhea, and constipation. He emphasizes the importance of dose escalation, a method where the dosage is gradually increased over time to minimize side effects, and dietary adjustments to mitigate these side effects.
Why it matters: While GLP-1 receptor agonists offer significant health benefits, managing their side effects is crucial for patient adherence and long-term success. Healthcare providers play a key role in guiding patients through these challenges, ensuring they can maintain their treatment and achieve their health goals.
Sex Drive and GLP-1 Drugs: What You Need to Know
Link: PureWow Article
What happens to your sex drive when you start taking GLP-1 drugs like Ozempic? According to Dr. Craig Primack, an obesity medicine specialist, there is no direct evidence linking GLP-1 medications to changes in sexual health. However, the weight loss and health improvements associated with these drugs can indirectly enhance sexual well-being. By reducing inflammation and improving hormone regulation, GLP-1 drugs may help restore normal sexual function in individuals affected by obesity.
Why it matters: Although there is no direct research on the impact of GLP-1 drugs on sexual health, the overall health benefits of weight loss can lead to improvements in sexual function. Patients should be aware of these potential benefits as part of their overall health journey with GLP-1 medications.
Can GLP-1 Drugs Help People Quit Smoking?
Link: Healthline Article
Recent studies suggest that GLP-1 drugs, including semaglutide, may help people quit smoking. Researchers believe these medications can reduce the cravings and withdrawal symptoms associated with nicotine addiction, making it easier for patients to stop smoking. This potential use of GLP-1 drugs could add another layer to their already extensive benefits.
Why it matters: If GLP-1 drugs prove effective in smoking cessation, they could offer a new tool for tackling nicotine addiction, further expanding the therapeutic uses of these medications. This could lead to broader applications for GLP-1 drugs, benefiting a wider range of patients beyond those seeking weight loss or diabetes management.
Expert Tweet of the Week
From @MichaelAlbertMD
"ZEPBOUND AND MOUNJARO are IN SHORTAGE but AVAILABLE. Please report on this accurately. It's available on the FDA website. If you don't understand the distinction, please ask me."
Read the related website page here
---
Our ModernWeight "Weekly Weight Management Insights" newsletter is designed to keep you informed and engaged with the latest in weight management and GLP-1 medications. Visit the Social Hub to join the conversation and connect with our community.
Want to receive this newsletter in your inbox weekly? Create a profile!
ความคิดเห็น